Titan Pharmaceuticals, Inc. (TTNP)
| Market Cap | 17.21M |
| Revenue (ttm) | 3.30M |
| Net Income (ttm) | -12.34M |
| Shares Out | 9.86M |
| EPS (ttm) | -1.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 111,440 |
| Open | 1.77 |
| Previous Close | 1.79 |
| Day's Range | 1.72 - 1.81 |
| 52-Week Range | 1.57 - 8.85 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 7.00 (+300.0%) |
| Est. Earnings Date | Nov 15, 2021 |
About TTNP
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment ...
Financial Performance
In 2020, TTNP's revenue was $4.84 million, an increase of 85.72% compared to the previous year's $2.61 million. Losses were -$18.24 million, 10.8% more than in 2019.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for TTNP stock is "Buy" and the 12-month stock price forecast is 7.00.
News
Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license ag...
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic ...
SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," former...
Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K
SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended Decembe...
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Develo...
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potenc...
Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institut...
Titan Pharmaceuticals Announces Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 rever...
TTNP Stock Price Increases 34.75%: Why It Happened
The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has increased by 34.75% from $0.13 per share to $0.17 per share. This is an explanation of why it happened.
Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30...
7 Penny Stocks to Watch in November
Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.
Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0....
Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Know about the JT Pharma Deal
Titan Pharmaceuticals (TTNP) is making news on Wednesday after announcing a deal with JT Pharma to acquire one of its assets. The post Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Kn...
Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing...
Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved th...
Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript
Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals To Report Second Quarter 2020 Financial Results On August 14, 2020
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation
SOUTH SAN FRANCISCO, Calif., July 8, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today urged its stockholders to vote "FOR" an amendment to its certificate...
Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership
SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Indegene Inc. ...
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript
Titan Pharmaceuticals Reports First Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended March 31, 202...
Penny Stocks to Buy Using Technical Analysis for April 2020
In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q3 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q3 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2019 Results - Earnings Call Transcript